Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Americans have had two extremely similar authorized COVID-19 vaccines since December: one mRNA vaccine from Pfizer, and another mRNA vaccine from Moderna. But now, there is another coronavirus shot authorized for use across the US: Johnson & Johnson's adenovirus jab, which got a green light from the US Food and Drug Administration on Saturday, after an expert committee unanimously recommended it should receive emergency use authorization Friday evening.

Here's why Johnson & Johnson's COVID-19 vaccine is arguably the best shot

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.

PreMarket Prep Stock Of The Day: Johnson & Johnson

Johnson & Johnson is waiting on regulatory approval of a new, larger plant operated by contract manufacturer Catalent Inc to begin large-scale U.S. deliveries of its just-authorized COVID-19 vaccine following initial shipments this week, a top J&J executive said on Monday.

Johnson & Johnson waiting on new plant approval to ship high volumes of vaccine: executive

In the U.S., the Johnson & Johnson shot has shown 72% effectiveness at preventing Covid and 86% effectiveness at preventing severe illness and death, according to data submitted to the FDA.

Johnson & Johnson's vaccine is approved — here's why experts say you should take what you can get

Just 10% of Americans have been fully vaccinated against Covid-19, according to the March IBD/TIPP Poll. But that could change after Johnson & Johnson's Covid jab was authorized.

Vaccine Acceptance Rises As Americans Eye Covid Mutations: IBD/TIPP Poll

Only time will tell what happens with bond yields — if they keep sinking stocks or if they cool off. In the meantime, the deep learning algorithms at Q.ai have rated the top trending stocks this week.

Johnson & Johnson Among Top Stocks To Buy This Week

It only requires one dose and doesn't need to be kept as cold. The first two COVID vaccines approved in the U.S. both use first-of-a-kind technology called messenger RNA.

This is how the Johnson & Johnson vaccine is different from Pfizer and Moderna's shots

The head of Johnson & Johnson said Americans should start receiving the company's COVID-19 vaccine within 48 hours, adding further ammunition to the effort to get jabs into arms and contain the pandemic that has killed more than half a million people.

Coronavirus Update: J&J CEO says Americans should start getting single-dose COVID vaccine within 48 hours

Johnson & Johnson (NYSE: JNJ) officially enters the fight against COVID-19 as its single-shot vaccine was approved over the weekend.

How Quickly Can Johnson & Johnson Deliver 100 Million COVID-19 Vaccine Doses?

Distribution began Monday for Johnson & Johnson's newly authorized one-shot coronavirus vaccine, leading JNJ stock to pop in early action. McKesson is distributing the J&J vaccine.

JNJ Stock Rises In Buy Zone As U.S. Begins Distributing Third Covid Vaccine

Johnson & Johnson (NYSE:JNJ) made headlines over the weekend, after its vaccine candidate received emergency use authorization from the Food and Drug Administration (FDA) over the weekend.

How Options Traders Are Playing JNJ's Big Vaccine News

Johnson & Johnson (NYSE:JNJ) has announced its one-shot COVID-19 vaccine has been approved by the US Food and Drug Administration. Developed by the Belgian arm Janssen, it is now available for individuals 18 years of age and older after it was shown to be 85% effective in late-stage clinical trials.

Johnson & Johnson receives US approval for COVID-19 vaccine, to test it on babies

J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.

FDA Emergency Nod for J&J COVID-19 Vaccine Heats Up Competition

On Feb 27, the United States sanctioned Johnson & Johnson's COVID-19 vaccine for emergency use, giving the nation a third vaccine to fight the outbreak, after BioNTech/Pfizer and Moderna.

How to Trade USFDA's EUA to J&J Vaccine With ETFs

J&J CEO Alex Gorsky told CNBC that the company's Covid-19 vaccine will be an important tool in the fight against the virus because it will prevent hospitalizations and deaths.

J&J CEO says single-shot Covid vaccine will keep people out of the hospital, prevent deaths

Approximately 16% of adults patients skipped flu shots due to a 'trypanophobia,' a fear of needles, according to one study.

Dispatches from a Pandemic: ‘I've been ready for this since this was declared a pandemic': J&J's one-shot COVID-19 vaccine is enticing for people who hate needles

The J&J vaccine was 66% effective overall compared with Pfizer's 95% and Moderna's 94% in clinical trials.

Fauci Urges Americans to Take Johnson & Johnson Vaccine Despite Concerns

The stock price of Johnson & Johnson (NYSE: JNJ) has increased by over 2.5% pre-market. This is why it happened.

JNJ Stock Price Increases Over 2.5% Pre-Market: Why It Happened

U.S. stock index futures jumped more than 1% on Monday as Johnson & Johnson's newly approved COVID-19 vaccine and progress in a new $1.9 trillion coronavirus relief package fueled optimism over a swift economic recovery.

Futures jump on J&J vaccine cheer, stimulus optimism

NEW BRUNSWICK, N.J., Feb. 28, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine,...

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.

CDC Director Dr. Rochelle Walensky said Friday that she would "stand by to review" the ACIP's recommendation and be "ready to sign."

CDC panel recommends use of J&J's single-shot Covid vaccine, clearing way for distribution

Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, said, ‘Be careful when you try to parse this percent versus that percent.'

Dr. Fauci on J&J's COVID-19 vaccine: ‘People need to get vaccinated ...I would have no hesitancy whatsoever to take it'

Here's what you need to know to navigate the markets today. Dr. Fauci on Johnson & Johnson vaccine, Virginia legalizes marijuana, Biden press secretary says president supports Bernie Sanders $14 minimum wage plan.

Fauci Urges Americans to Take Johnson & Johnson Vaccine

The big pharmaceutical company's jab has some important advantages.

Johnson & Johnson Coronavirus Vaccine Wins FDA Authorization

Dr. Anthony Fauci on Sunday said he trusts the Johnson & Johnson vaccine, the latest to get authorized for emergency use by the Food and Drug Administration.  Johnson & Johnson is offering a single-dose vaccine that the company expects to distribute to 4 million Americans shortly. The FDA approved the vaccine on Saturday, marking the third one available in the United States.

News for Johnson & Johnson Stock (JNJ)